H.C. Wainwright lowered the firm’s price target on Aligos Therapeutics (ALGS) to $70 from $75 and keeps a Buy rating on the shares. The firm is adding the Chinese HBV market into its ALG-000184 revenue projection model, in addition to the U.S. and the EU5 markets that are currently in the model, and now projects ALG-000184 to reach peak total revenues of close to $2B in 2040, the analyst tells investors in a post-Q4 note.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics Advances Pipeline Amid Financial Challenges
- Aligos Therapeutics reports Q4 EPS ($13.08) vs ($5.50) last year
- ALGS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Aligos Therapeutics Secures $105M in Private Placement
- Aligos Therapeutics announces $105M private placement financing